The filing is a routine advance notice of an insider sale; the actual sale may or may not occur. No material impact expected. Monitor for any subsequent Form 4 filings to confirm execution.
MRK drugs
MRK drug pipeline →- ● ENFLONSIA 4/10 Approved · PDUFA date Mar 22, 2027
- ● IDVYNSO 4/10 Approved · PDUFA date Apr 22, 2027
- ▲ sac-TMT 6/10 Filed/PDUFA (Phase 3 data complete; BLA under priority review) · PDUFA date Jun 15, 2027
- ● GARDASIL 4/10 Approved
- ● LAGEVRIO 4/10 EUA (Emergency Use Authorization) / Marketed
- 15 more · All MRK drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $147.76entry
- T+1 · 16h ago −2.23%α −0.32% · $144.46
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Richard R. DeLuca Jr., an officer of Merck, filed a Form 144 notice of intent to sell 58,185 shares of common stock, with an approximate market value of $8.6 million based on the filing date. The shares were acquired through exercise of options under a registered plan. The sale is a routine insider transaction and represents a small fraction of Merck's market cap.
Key Facts
- Richard R. DeLuca Jr., an officer of Merck, filed Form 144 on 2026-11-12
- Proposed sale of 58,185 shares of common stock
- Estimated aggregate market value of $8,611,874.57
- Shares acquired via exercise of options under a registered plan on 2026-11-12
- Sale intended to be executed on NYSE
- Prior sale of 11,699 shares on 2026-08-12 valued at $1,539,992.02
Financial Impact
Proposed sale of 58,185 shares valued at approximately $8.6 million, a small fraction of Merck's market cap
Risk Factors
- Insider sale may signal personal liquidity needs rather than negative outlook
- Sale is not yet executed; Form 144 is only an intent to sell
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-011026 |
| Document: 0001950047-26-011026-index.html | 0001950047-26-011026 |
| Document: 0001950047-26-011026.txt | 0001950047-26-011026 |
Track record
34 reports on MRK
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.92% at T+20 after the Aug 6, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $147.76 Now $144.46 −2.23% settles Feb 11
- Nov 9, 20268d ago PTAB Trial Neutral 2/10 Entry $148.05 Now $144.46 −2.42% settles Feb 8
- Nov 3, 202613d ago 3 Neutral 2/10 Entry $144.67 Now $144.46 −0.15% settles Feb 1
- Nov 3, 202613d ago Institutional Cluster Bearish 4/10 Entry $144.67 Now $144.46 +0.15% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $144.67 Now $144.46 −0.15% settles Feb 1
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $146.33 Now $144.46 −1.28% settles Jan 27
- Oct 22, 202625d ago 3/A Neutral 1/10 Entry $145.27 Now $144.46 −0.56% settles Jan 21
- Oct 21, 202627d ago PTAB Trial Neutral 3/10 Entry $147.24 Now $144.46 −1.89% settles Jan 20
- Oct 15, 20264w ago PTAB Trial Bullish 6/10 Entry $145.95 Now $144.46 −1.02% settles Jan 13
- Oct 15, 20264w ago PTAB Trial Bullish 5/10 Entry $145.95 Now $144.46 −1.02% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers